Rejuven Dermaceutical held pre-IND meeting with FDA of the US on January 14, 2019. Rejuven’s RJV001 as a new BLA will seek IND approval, and its development process including CMC, non clinical and cl...
Rejuven Dermaceutical was invited to present its drug development business in the Biotech Showcase during the JP Morgan Healthcare Investment meeting in San Francisco on January 7-9, 2019. Over 3600 i...
Rejuven won the 3rd place in 2018 SATOL (China) Roadshow The Second SATOL (China) Global Conference on Life Sciences and Technology was held in Hangzhou on December 8, attracting more than 30 academy ...
In November 2018, Rejuven Dermaceutical was awarded the selective honor of “Enterprise of Hangzhou Science & Technology Startup Incubation Project in 2018”.
On September 16, 2018 Rejuven Dermaceutical was invited to present in the Second Chinese Medical Esthetics Investment Summit held by Chinese Association of Plastics and Aesthetics in Shanghai. Rejuven reported its latest R & D update and financial prospect to the attending medical professionals, government agencies, pharmaceutical enterprises, venture capital firms.
In August 2018, Rejuven Dermaceutical was awarded the selective honor of “Hangzhou High-tech Enterprise” presented by Hangzhou Municipal Bureau of Science and Technology.